

Ipca Laboratories (IPCA IN)

Rating: BUY | CMP: Rs1,423 | TP: Rs1,826

February 13, 2020

Q3FY20 Result Update

☒ Change in Estimates | ☒ Target | ☒ Reco

Change in Estimates

	Current		Previous	
	FY21E	FY22E	FY21E	FY22E
Rating	BUY		ACCUMULATE	
Target Price	1,826		1,238	
Sales (Rs. m)	51,066	57,626	50,363	57,311
% Chng.	1.4	0.6		
EBITDA (Rs. m)	11,362	13,398	9,342	10,631
% Chng.	21.6	26.0		
EPS (Rs.)	65.8	78.4	48.6	55.8
% Chng.	35.2	40.3		

Key Financials - Standalone

Y/e Mar	FY19	FY20E	FY21E	FY22E
Sales (Rs. m)	37,732	44,799	51,066	57,626
EBITDA (Rs. m)	6,919	9,542	11,362	13,398
Margin (%)	18.3	21.3	22.3	23.3
PAT (Rs. m)	4,396	6,877	8,308	9,900
EPS (Rs.)	34.8	54.4	65.8	78.4
Gr. (%)	83.4	56.4	20.8	19.2
DPS (Rs.)	-	-	-	-
Yield (%)	-	-	-	-
RoE (%)	15.1	19.8	19.7	19.3
RoCE (%)	15.0	20.5	21.1	21.2
EV/Sales (x)	4.8	4.0	3.4	2.9
EV/EBITDA (x)	26.0	18.6	15.3	12.5
PE (x)	40.9	26.1	21.6	18.2
P/BV (x)	5.8	4.7	3.9	3.2

Key Data

IPCA.BO | IPCA IN

52-W High / Low	Rs.1,441 / Rs.740
Sensex / Nifty	41,460 / 12,175
Market Cap	Rs.180bn/ \$ 2,519m
Shares Outstanding	126m
3M Avg. Daily Value	Rs.420.4m

Shareholding Pattern (%)

Promoter's	46.07
Foreign	13.99
Domestic Institution	25.93
Public & Others	14.01
Promoter Pledge (Rs bn)	-

Stock Performance (%)

	1M	6M	12M
Absolute	20.0	52.3	89.4
Relative	21.2	35.8	64.6

Surajit Pal

surajitpal@plindia.com | 91-22-66322259

Tausif Shaikh

tausifshaikh@plindia.com | 91-22-66322246

Robust growth across segments – Upgrade to BUY

Quick Pointers:

- India formulations outperform Industry (IPM) growth
- Guided: API to grow 15-16% in Q4FY20E.

IPCA reported strong Q3FY20 earning with Revenue, EBITDA, and PAT increasing by 20%, 15%, and 23% YoY to Rs11.4bn (PLe 11.9bn), Rs2.7 (PLe 2.7bn), and Rs1.9bn (PLe 1.9bn). Its 85% of formulations are integrated with captive APIs while only top 8-10 APIs are integrated with key ingredients. With inventory of ingredients/API till April, management guided that manufacturing of pharma chemicals need to be normalised in China by mid-March. The delay beyond mid-March will impact productions of key APIs and formulations in IPCA.

EBITDA margin guided to improve by 100-150 bps YoY in FY21E and FY22E due to the benefits of operating leverage, re-entry in UK generics, traction in branded generics and strong demand of high value APIs. We expect Global Fund business may shift some of its sales to FY21E. IPCA trades at PER of 21.6x (FY21E) and 18x (FY22E). We have increased our earnings estimate by 34% (FY21E) and 40% (FY22E) and increased our PE multiple to 23.3x(earlier 22x)due to better visibility in tender business, generic export and reduction in effective tax rate.We have upgraded the stock to 'BUY' from Accumulate with TP to Rs1826 (from Rs1238) on PE 23.3x of FY22 earnings.

Conference Call and other key highlights:

- Formulation:** Revenue grew 19% YoY led by growth in India and export markets of 15% and 25% YoY, respectively. In exports, its branded, institutional, and generics grew 8%, 23% and 39% YoY, respectively.
- India Formulations:** Top 10 brands contributed 55% of the domestic revenue and it grew 19% YoY. IPCA further strengthen its presence in pain management (PMS) with growth of 19% YoY in Q3FY20. Contribution from PMS is increased to 47% (vs. 45.5% in FY15) of India revenue, while other therapies like Diabetes, anti-Bacteria, Derma and Cough/cold contributed 18%, 8%, 5% and 4% of the domestic revenues and those also grew at 9%, 34%, 17% and 8% YoY. IPCA has a team of 4,600 MRs in India with productivity of Rs10 Lac/ month for rheumatoid arthritis segment (PMS) though majority of the products in the portfolio are in NLEM list.
- Exports:** Institutional Business grew 23% YoY, while declined 22% QoQ due to weak orders from Global fund. IPCA guided revenue of Rs1,800m in FY20E and Rs2,500m in FY21E. Branded generics business grew 8% YoY and 13% QoQ, led by growth across regions (Europe, Canada, Africa, Australia and New Zealand).

- **API :** Revenue grew 24% YoY and declined 9% QoQ due to stabilization in Sartan prices. IPCA focuses on de-bottle necking of current plants of API and plan for expansion in FY22E. Capacity utilization at API unit in Ratlam was at 90%, while intermediaries plant of Aurangabad and Mahad are running at full capacity
- **Regulatory Status:** Ratlam, Silvasa and Indore Piparia continues to be under USFDA import alert. IPCA completed remediation work for Silvasa is awaiting response from the regulator.
- **Subsidiaries:** Total revenue from subsidiaries were Rs740m with Bayshore, Ramdev and Pigsaw contributed Rs410m, Rs150m and Rs180m in Q3FY20.
- **Noble Explochem:** During Q3FY20, IPCA acquired Noble Explochem. The plant has been not operational since 2006 and it will take further 15-18 months to commercialize. IPCA plans to utilize the plant to produce KSM and reduce its dependence on Chinese import.

Exhibit 1: Q3FY20 Result Overview (Rs mn)

Y/e March	Q3FY20	Q3FY19	YoY gr. (%)	Q2FY20	9MFY20	9MFY19	YoY gr. (%)
Net Sales	11,390	9,476	20.2	12,126	33,626	27,993	20.1
Raw Material	3,815	2,997	27.3	4,097	11,538	8,908	29.5
<i>% of Net Sales</i>	<i>33.5</i>	<i>31.6</i>		<i>33.8</i>	<i>34.3</i>	<i>31.8</i>	
Personnel Cost	2,177	1,763	23.5	2,197	6,429	5,754	11.7
<i>% of Net Sales</i>	<i>19.1</i>	<i>18.6</i>		<i>18.1</i>	<i>19.1</i>	<i>20.6</i>	
Others	2,744	2,399	14.4	3,217	8,439	8,146	3.6
<i>% of Net Sales</i>	<i>24.1</i>	<i>25.3</i>		<i>26.5</i>	<i>25.1</i>	<i>29.1</i>	
Total Expenditure	8,736	7,159	22.0	9,510	26,406	22,808	15.8
EBITDA	2,654	2,317	14.5	2,616	7,220	5,185	39.2
<i>Margin (%)</i>	<i>23.3</i>	<i>24.5</i>		<i>21.6</i>	<i>21.5</i>	<i>18.5</i>	
Depreciation	461	426	8.2	451	1,333	1,303	2.3
EBIT	2,193	1,891	16.0	2,165	5,887	3,882	51.6
Other Income	176	126	39.6	143	514	400	28.4
Interest	38	49	(22.9)	41	123	122	0.7
PBT	2,331	1,968	18.5	2,267	6,278	4,160	50.9
Extra-Ord. Inc./Exps.	-	-		-	-	-	
Total Taxes	365	366	(0.3)	307	1,031	706	46.1
<i>ETR (%)</i>	<i>15.7</i>	<i>18.6</i>		<i>13.5</i>	<i>16.4</i>	<i>17.0</i>	
Reported PAT	1,966	1,602	22.7	1,960	5,247	3,454	51.9
Other Comprehensive Income	-	(12)		(33)	(42)	(9)	
Total Comprehensive Income	1,966	1,590	23.7	1,927	5,205	3,446	51.1


Source: Company, PL

Exhibit 2: Major Sources of Revenue

Major sources of revenues	Q3FY20	Q3FY19	YoY gr. (%)	Q2FY20	9MFY20	9MFY19	YoY gr. (%)
Domestic	5,388	4,661	15.6	6,104	16,677	14,471	15.2%
Formulations	4,856	4,216	15.2	5,432	14,817	12,911	14.8%
APIs	532	445	19.5	672	1,861	1,559	19.3%
Exports	5,856	4,680	25.1	5,880	16,511	13,117	25.9%
Formulations	3,534	2,824	25.2	3,408	9,391	7,946	18.2%
APIs	2,322	1,856	25.1	2,472	7,120	5,170	37.7%
Net Sales	11,244	9,340	20.4	11,984	33,188	27,587	20.3%


Source: Company, PL

Exhibit 3: Total Sales and growth




Source: Company, PL

Exhibit 4: India formulations sales, growth




Source: Company, PL

Exhibit 5: Export formulation sales, growth




Source: Company, PL

Exhibit 6: Domestic API Sales and growth




Source: Company, PL

Exhibit 7: Export API sales and growth



Source: Company, PL

Exhibit 8: EBITDA Margin



Source: Company, PL

Financials

Income Statement (Rs m)

Y/e Mar	FY19	FY20E	FY21E	FY22E
Net Revenues	37,732	44,799	51,066	57,626
YoY gr. (%)	14.9	18.7	14.0	12.8
Cost of Goods Sold	12,397	15,344	17,031	19,190
Gross Profit	25,334	29,456	34,036	38,437
Margin (%)	67.1	65.8	66.7	66.7
Employee Cost	7,874	8,624	9,447	10,056
Other Expenses	943	1,210	1,328	1,441
EBITDA	6,919	9,542	11,362	13,398
YoY gr. (%)	52.2	37.9	19.1	17.9
Margin (%)	18.3	21.3	22.3	23.3
Depreciation and Amortization	1,824	1,826	2,026	2,215
EBIT	5,094	7,717	9,337	11,184
Margin (%)	13.5	17.2	18.3	19.4
Net Interest	189	157	113	106
Other Income	577	681	721	765
Profit Before Tax	5,482	8,240	9,945	11,843
Margin (%)	14.5	18.4	19.5	20.6
Total Tax	1,042	1,318	1,591	1,895
Effective tax rate (%)	19.0	16.0	16.0	16.0
Profit after tax	4,440	6,922	8,354	9,948
Minority interest	44	45	46	48
Share Profit from Associate	-	-	-	-
Adjusted PAT	4,396	6,877	8,308	9,900
YoY gr. (%)	83.6	56.4	20.8	19.2
Margin (%)	11.7	15.3	16.3	17.2
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	4,396	6,877	8,308	9,900
YoY gr. (%)	83.6	56.4	20.8	19.2
Margin (%)	11.7	15.3	16.3	17.2
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	4,396	6,877	8,308	9,900
Equity Shares O/s (m)	126	126	126	126
EPS (Rs)	34.8	54.4	65.8	78.4

Source: Company Data, PL Research

Balance Sheet Abstract (Rs m)

Y/e Mar	FY19	FY20E	FY21E	FY22E
Non-Current Assets				
Gross Block	25,870	27,920	29,970	32,020
Tangibles	23,940	25,840	27,740	29,640
Intangibles	1,930	2,080	2,230	2,380
Acc: Dep / Amortization	6,938	8,764	10,789	13,004
Tangibles	6,475	8,139	9,986	12,004
Intangibles	463	624	803	1,000
Net fixed assets	18,932	19,156	19,181	19,016
Tangibles	17,465	17,700	17,753	17,636
Intangibles	1,467	1,456	1,427	1,380
Capital Work In Progress	663	597	635	611
Goodwill	472	472	472	472
Non-Current Investments	1,503	1,744	2,032	3,071
Net Deferred tax assets	(1,457)	(1,640)	(1,839)	(2,076)
Other Non-Current Assets	141	169	203	608
Current Assets				
Investments	904	922	968	1,452
Inventories	10,725	13,010	14,830	16,577
Trade receivables	6,815	8,837	10,493	11,841
Cash & Bank Balance	2,823	3,854	6,173	12,055
Other Current Assets	1,434	1,577	1,814	2,358
Total Assets	45,507	51,522	58,160	69,949
Equity				
Equity Share Capital	253	253	253	253
Other Equity	30,971	37,848	46,156	56,056
Total Network	31,224	38,101	46,408	56,308
Non-Current Liabilities				
Long Term borrowings	1,409	1,056	687	652
Provisions	253	303	243	255
Other non current liabilities	16	14	13	11
Current Liabilities				
ST Debt / Current of LT Debt	2,097	1,258	818	859
Trade payables	5,243	6,137	5,876	7,105
Other current liabilities	3,635	3,012	2,277	2,683
Total Equity & Liabilities	45,507	51,522	58,161	69,949

Source: Company Data, PL Research

**Cash Flow (Rs m)**

Y/e Mar	FY19	FY20E	FY21E	FY22E
PBT	4,440	6,922	8,354	9,948
Add. Depreciation	1,824	1,826	2,026	2,215
Add. Interest	189	157	113	106
Less Financial Other Income	577	681	721	765
Add. Other	(1,144)	1,683	3,976	(9,629)
Op. profit before WC changes	5,309	10,587	14,468	2,639
Net Changes-WC	(130)	(4,259)	(4,861)	(2,546)
Direct tax	(1,069)	(1,883)	(1,892)	(1,892)
Net cash from Op. activities	4,110	4,445	7,715	(1,799)
Capital expenditures	(1,641)	(2,014)	(2,115)	(1,953)
Interest / Dividend Income	4	5	5	5
Others	(281)	(91)	(121)	(561)
Net Cash from Invst. activities	(1,918)	(2,100)	(2,231)	(2,509)
Issue of share cap. / premium	-	-	-	-
Debt changes	(1,282)	(1,254)	(3,875)	8,616
Dividend paid	-	-	-	-
Interest paid	(189)	(157)	(113)	(106)
Others	-	-	-	-
Net cash from Fin. activities	(1,471)	(1,411)	(3,988)	8,510
Net change in cash	721	934	1,496	4,202
Free Cash Flow	2,469	2,431	5,600	(3,752)

Source: Company Data, PL Research

Quarterly Financials (Rs m)

Y/e Mar	Q4FY19	Q1FY20	Q2FY20	Q3FY20
Net Revenue	8,338	10,110	12,126	11,390
YoY gr. (%)	6.7	18.4	21.5	20.2
Raw Material Expenses	2,690	3,626	4,097	3,815
Gross Profit	5,648	6,484	8,029	7,575
Margin (%)	67.7	64.1	66.2	66.5
EBITDA	1,747	1,950	2,616	2,654
YoY gr. (%)	60.7	71.1	51.4	14.5
Margin (%)	20.9	19.3	21.6	23.3
Depreciation / Depletion	416	420	451	461
EBIT	1,331	1,530	2,165	2,193
Margin (%)	16.0	15.1	17.9	19.3
Net Interest	63	45	41	38
Other Income	146	194	143	176
Profit before Tax	1,414	1,680	2,267	2,331
Margin (%)	17.0	16.6	18.7	20.5
Total Tax	319	359	307	365
Effective tax rate (%)	22.6	21.4	13.5	15.7
Profit after Tax	1,095	1,321	1,960	1,966
Minority interest	-	-	-	-
Share Profit from Associates	-	-	-	-
Adjusted PAT	1,095	1,321	1,960	1,966
YoY gr. (%)	113.4	101.5	63.7	22.7
Margin (%)	13.1	13.1	16.2	17.3
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	1,095	1,321	1,960	1,966
YoY gr. (%)	113.4	101.5	63.7	22.7
Margin (%)	13.1	13.1	16.2	17.3
Other Comprehensive Income	(43)	(9)	(33)	-
Total Comprehensive Income	1,052	1,312	1,927	1,966
Avg. Shares O/s (m)	126	126	126	126
EPS (Rs)	8.7	10.5	15.5	15.6

Source: Company Data, PL Research

Key Financial Metrics


Y/e Mar	FY19	FY20E	FY21E	FY22E
Per Share(Rs)				
EPS	34.8	54.4	65.8	78.4
CEPS	49.2	68.9	81.8	95.9
BVPS	247.1	301.5	367.3	445.7
FCF	19.5	19.2	44.3	(29.7)
DPS	-	-	-	-
Return Ratio(%)				
RoCE	15.0	20.5	21.1	21.2
ROIC	13.7	19.8	21.2	23.9
RoE	15.1	19.8	19.7	19.3
Balance Sheet				
Net Debt : Equity (x)	0.0	(0.1)	(0.1)	(0.2)
Net Working Capital (Days)	119	128	139	135
Valuation(x)				
PER	40.9	26.1	21.6	18.2
P/B	5.8	4.7	3.9	3.2
P/CEPS	28.9	20.7	17.4	14.8
EV/EBITDA	26.0	18.6	15.3	12.5
EV/Sales	4.8	4.0	3.4	2.9
Dividend Yield (%)	-	-	-	-

Source: Company Data, PL Research

Key Operating Metrics

Y/e Mar	FY19	FY20E	FY21E	FY22E
Domestic Formulations	16,468	18,939	21,590	24,397
Domestic API	2,020	2,343	2,624	2,887
Export Formulations	10,483	12,398	14,708	16,862
Export API	6,826	9,127	10,131	11,448

Source: Company Data, PL Research

Price Chart
Recommendation History


No.	Date	Rating	TP (Rs.)	Share Price (Rs.)
1	3-Jan-20	Accumulate	1,238	1,139
2	8-Nov-19	Accumulate	1,238	1,074
3	3-Oct-19	Accumulate	1,008	905
4	14-Aug-19	Accumulate	1,008	940
5	4-Jul-19	BUY	908	949
6	5-Apr-19	BUY	921	957
7	6-Mar-19	BUY	921	873

Analyst Coverage Universe

Sr. No.	Company Name	Rating	TP (Rs)	Share Price (Rs)
1	Aurobindo Pharma	Hold	525	547
2	Cadila Healthcare	Hold	247	272
3	Cipla	Reduce	460	448
4	Dr. Lal PathLabs	Hold	1,797	1,741
5	Dr. Reddy's Laboratories	Accumulate	3,331	3,200
6	Eris Lifesciences	Accumulate	459	490
7	Glenmark Pharmaceuticals	Reduce	335	352
8	Indoco Remedies	Hold	198	234
9	Ipca Laboratories	Accumulate	1,238	1,139
10	Jubilant Life Sciences	Reduce	488	583
11	Lupin	Reduce	654	722
12	Sun Pharmaceutical Industries	Reduce	412	431
13	Thyrocare Technologies	BUY	724	603

PL's Recommendation Nomenclature (Absolute Performance)

Buy	: > 15%
Accumulate	: 5% to 15%
Hold	: +5% to -5%
Reduce	: -5% to -15%
Sell	: < -15%
Not Rated (NR)	: No specific call on the stock
Under Review (UR)	: Rating likely to change shortly

ANALYST CERTIFICATION

(Indian Clients)

We/I, Mr. Surajit Pal- PGDBA, CFA, M.Com, Mr. Tausif Shaikh- BA, Major in Economics, Financial Management Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

(US Clients)

The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report.

DISCLAIMER

Indian Clients

Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as "PL") is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd. which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at www.plindia.com.

This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security.

The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein.

Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor.

Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.

PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document.

PL is in the process of applying for certificate of registration as Research Analyst under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities.

PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company.

PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.

PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report.

PL or its associates might have received compensation from the subject company in the past twelve months.

PL or its associates might have managed or co-managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months.

PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.

PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months

PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report.

PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report. PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report. PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report.

It is confirmed that Mr. Surajit Pal- PGDBA, CFA, M.Com, Mr. Tausif Shaikh- BA, Major in Economics, Financial Management Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company

Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

US Clients

This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo").

Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

Prabhudas Lilladher Pvt. Ltd.

3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai-400 018, India | Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209

www.plindia.com